Richard M Goldberg , MD

Professor Emeritus

Organization:

West Virginia University School of Medicine

Department:

Medicine

Classification:

Faculty

• MD, State University of New York Upstate Medical University, 1979

Ten Most Recent:

Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer.
Taieb J, Le Malicot K, Shi Q, Penault Lorca F, Bouche O, Tabernero J, Mini E, Goldberg RM, Folprecht G, Luc Van Laethem J, Sargent DJ, Alberts SR, Francois Emile J, Laurent Puig P, Sinicrope FA.
J Natl Cancer Inst. 2017; 109(5).
In process

A study of thymidylate synthase expression as a biomarker for resectable colon cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.
Oncologist. 2017; 22(1): 107-114.
In Process

Reply to L. Casadaban et al.
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.
J Clin Oncol. 2017: JCO2016712646.

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.
Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X.
Sci Rep. 2016; 6: 33273.
PMC5021945

Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers : a secondary analysis of 2 randomized clinical trials.
Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.
JAMA Oncol. 2016.

Relationship between metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance).
Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR.
Oncologist. 2016; 21(12): 1509-1521.
PMC5153338

Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database.
Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ.
J Clin Oncol. 2016; 34(2): 144-150.
PMC5070548

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147.
Phipps AI, Shi Q, Limburg PJ, Nelson GD, Sargent DJ, Sinicrope FA, Chan E, Gill S, Goldberg RM, Kahlenberg M, Nair S, Shields AF, Newcomb PA, Alberts SR, Alliance for Clinical Trials in O.
Int J Cancer. 2016; 139(5): 986-995.
PMC4911257

Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer.
Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H, Ohio Colorectal Cancer Prevention Initiative Study G.
JAMA Oncol. 2016.

Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in Cancer and Leukemia Group B 9581 (Alliance).
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.
J Clin Oncol. 2016; 34(25): 3047-3053.
PMC5012711
 

2016 Award for Outstanding Patient Satisfaction
2016 ASCO Advocacy Champion
2015 One of five nominees; Giants in Oncology Award for Gastrointestinal Cancer (award pending)
2013 Bob Pinedo Cancer Care Prize, Lectureship: Ten Years of Progress in the Management of Colorectal Cancer at the GI Cancer Symposium
Elected to be a Fellow of the American Society of Clinical Oncology
2012 Charles G. Moertel Lectureship, The Alliance for Clinical Trials in Oncology
2011 ASCO Statesman Award, Third Susan Treadwell Fellow, Providence Hospital – Anchorage, Alaska
2006-2007 President, International Society of Gastrointestinal Oncology
2007 Volkman Memorial Lectureship, Eastern Carolina University – Greenville, NC
2006 Susan B. Lester Lectureship in Cancer at the University of Kentucky – Lexington, KY
2005 Frisbee Memorial Lectureship, Yale University – New Haven, CT
2003 Mayo Clinic Individual Achievement Award, Recipient “Cancer Fighting Hero” award from Minnesota State Division of the American Cancer Society
Identified as one of 318 Leading Cancer Specialists by Good Housekeeping
2001-Present Listing in The Best Doctors in America
2004-Present Listing in Best Oncologists
2001-Present Listing in Castle Connolly Best Doctor
Listing in Who’s Who in Engineering and Science
Listing in Who’s Who in the World
Listing in 2000 Notable American Men
Listing in Who’s Who

1986 & 1987 Commendations for Teaching Excellence
1989 Fellow, American College of Physicians
1978 Alpha Omega Alpha Membership
1975 AB cum Laude, Harvard University

NATIONAL MEMBERSHIPS AND INTERNATIONAL OFFICES OR COMMITTEES

• Alpha Omega Alpha Honor Medical Society
• American Association of Cancer Research
• American Clinical and Climatological Association
• American College of Physicians (Fellow)
• NCI Colorectal Task Force, 2000-
• American Joint Committee on Cancer
• Co-Chair Colorectal and Anal Cancer Staging Committee 2013- present
• Board of Directors 2005-2013
• Finance Committee 2008-2013
• Promotions Committee 2008-2013
• Co-Chair, Colorectal Cancer Staging Working Group for the 8^th Edition of Cancer Staging - 2014
• American Medical Association
• American Society of Clinical Oncology (ASCO): Member, Annual meeting Program Committee, 1991-1992, 2000-2002, 2007-2011. Member, Education Committee, 1997-2000. Member, Publications Committee 2003-2006
•  Member, Program Committee for the GI Cancer Symposium 2006-2007
•  Member, Steering Committee for the GI Cancers Symposium 2010 and 2011
• Chair, Steering Committee for the GI Cancers Symposium 2012
• Editorial Board, GI cancer editor, Cancer.Net 2005-2014
• Editorial Board, Journal of Clinical Oncology 2001-2003
• Member, Ethics Committee, 2007-2010
• Mentor, ASCO International Development and Education Program (IDEA), 2007-10
• Recipient, ASCO Statesman Award, 2011
• Fellow, American Society of Clinical Oncology, 2013
• Member, Governmental Affairs Committee, 2013-
• Member, Dana Farber/ Harvard Cancer Center External Advsory Board, 2010
• Society for Translational Oncology, Board of Directors, 2009-
• Zumbro Valley Medical Society, 1996-2003
• Minnesota Medical Society Annual meeting, Delegate, 1999
• Association of Program Directors of Internal Medicine, 1992-94
• American College of Physician Executives, 1992-94
• ASCO Representative to the American Society for Radiology Oncology (ASTRO) Rectal Cancer Best Practice Expert Panel Meeting - Washington, DC - 2014

Richard M Goldberg, MD, is West Virginia University Cancer Institute’s (WVUCI) Director, and Director of the WVU Cancer Signature Program. He serves as a member of WVU health sciences Vice President and Executive Dean, Clay Marsh’s leadership team.  As WVUCI’s Director, he oversees the clinical, research, and teaching missions of the cancer institute and its component organizations that include satellite clinical and clinical research locations that are dispersed throughout West Virginia.

Considered an international leader in gastrointestinal cancer treatment and research as well as in leadership of cancer programs in academic medicine, Dr. Goldberg has been principal investigator, co-PI, co-investigator and mentor on multiple research and training grants funded through the National Cancer Institute (NCI). He has published more than 320 papers in peer-reviewed journals. His clinical interests are in management of patients with malignancies originating in the gastrointestinal tract, particularly colorectal and neuroendocrine cancers. His research focuses on defining new treatments, elucidating inherited cancer susceptibility, and identification of predictive and prognostic factors in GI cancers. He helps to lead the Alliance for Clinical Trials in Oncology as the Associate Group Chair of this NCI funded organization that is a member of the National Clinical Trials Network. The Alliance conducts clinical trials and does translational research across the US and Canada.

He is a sought after lecturer at academic centers and scientific conferences across the nation and the world. He has mentored many MD, MD/PhD, and PhD doctoral students, post-doctoral researchers and junior faculty over his 33 years as a medical oncologist in academic settings.

He is a graduate of Harvard University, earning an undergraduate degree cum laude in biology in 1975 and received his medical degree from the State University of New York Upstate Medical University in 1979 where he was elected to the Alpha Omega Alpha honor medical society.

Prior to his arrival at WVU in 2017, he served as physician in chief of the both the James Cancer Hospital at The Ohio State University (OSU) and, prior to that of the North Carolina Cancer Hospital, at the University of North Carolina in Chapel Hill (UNC). He was an Associate Director at both the OSU and the UNC Comprehensive Cancer Centers and the Division Chief of Hematology and Oncology at UNC and Acting Division Director of Medical Oncology at OSU. Prior to that he was a consultant at the Mayo Clinic in Rochester and Associate Chair of the Department of Medicine at the Geisinger Clinic in Danville, PA.  

Dr. Goldberg serves on several national scientific advisory committees and on the scientific advisory committee for a number of pharmaceutical companies at the corporate level. He is a Fellow in the American College of Physicians and the American Society of Clinical Oncology. He is married to Lynda Goldberg MBA, MPH and has two adult children.

Non-Programmatically Aligned Cancer Center Member

Dr. Goldberg’s research interests include focus on GI cancer and include new drug development through design and management of clinical trials, understanding inherited cancer susceptibility, discovery of markers in tumors that predict outcomes and drug sensitivity or resistance, and pooling data from patients enrolled across multiple clinical trials to extract as much value as possible from the outcome of each person who enrolled. His career has spanned three decades and he has been an author on over 300 peer reviewed publications with coauthors that range from students to internationally known researchers from around the globe. His research illustrates the value of collaboration. The major emphasis is on the biology and treatment of colorectal cancer. His most impactful work was a study funded by the NCI through a program now known as the National Clinical Trials Network.  That study led to the licensing in the U.S. of the drug oxaliplatin for the indication of initial treatment of patients with metastatic colorectal cancer and the adoption of a treatment program known as FOLFOX that includes folinic acid, 5-fluoruracil and oxaliplatin. That regimen remains the standard of care for these patients more than a decade later. Additional analyses from that study led to over 30 articles after the original paper was published. He served as the GI Cancer Committee chair for two of the NCI cooperative groups and remains involved in helping to set the national agenda for investigation of new therapies through the governmentally funded cooperative oncology groups. He has worked with collaborators across the US and Canada to understand inherited susceptibilities to colorectal cancer.  That research has focused on Lynch Syndrome which is responsible for early onset colon (and other cancers) and accounts for about 5% of people with the disease. He has also worked with colleagues at Johns Hopkins and other universities to discover that the PD-1 inhibitor pembrolizumab, one of a class of drugs that allows the body’s own immune cells to recognize cancer cells and destroy them,  is exceptionally effective in these patients. In collaborations with laboratory based researchers he has used tissues and other specimens obtained from patients enrolling in trials to elucidate the biology of colon cancers and exploit those finding to fine tune treatment choices for individuals. One ongoing study is comparing the genetic makeup of patients and their tumors to isolate markers that predict which patients will and will not have recurrent disease after surgery and chemotherapy for localized colon cancer. He has been a founding collaborator on several large collaborative networks that pool data cross studies, a process that give more power to statistical analyses. One study showed that the number of patients who are free of progression at 3 years is a reliable indicator of drug treatment efficacy in localized colon cancer, a finding that allows study results to be available early, prior to overall survival data at 5 years. This speeds the application of new regimens to the clinic. He intends to remain active in these endeavors at WVU.

• 1U10CA180850-01   (Goldberg)  05/06/2014-02/28/2019   20% effort   NIH/NCI   National Clinical Trials Network - Network Lead Academic Participating Sites (U10) This grant funds the OSU cooperative group academic participation and accrual program.

• 5K12CA133250-07   (Byrd)  06/01/2015-05/31/2019  1% effort   NIH/NCI Training grant for junior faculty in Hematology and Oncology

• CA128590-01A1   (Goldberg)   09/01/2008-08/31/2013   10% effort   NIH/NCI  Academic Training in Oncology at the University of North Carolina at Chapel Hill.  This T32 provides funds for training fellows interested in careers in academic oncology during their second and third fellowship years.

• 5R25CA116339-02   (Goldberg)  09/01/2008-08/31/2013  10% effort   NIH/NCI   National Cancer Institute (NCI) Cancer Education and Career Development Program. This R25 provides funds for training fellows and postdoctoral students interested in careers in public health.

• 1K12CA120780-01A1   (Goldberg)  09/12/2007-8/31/2012  10% effort   NIH/NCI  UNC Oncology Clinical Translational Research training Program. This K12 provides funds for training young investigators interested in cancer research for careers in that arena.

• P30 CA16086-30   (Earp)  12/01/2010-11/30/2011  20% effort   NIH/NCI   Lineberger Comprehensive Cancer Center Support Grant. The CCSG provides support for Cancer Center research programs, core facilities, administration, and related activities.

• No assignment #   (Bertagnolli)    09/01/2004-open ended   10% effort#   Alliance for Clinical Trials in Oncology Foundation. National Cancer Institute (NCI) Cancer Education and Career Development Program. Funds position as Associate Group Chair for Intergroup Affairs for this national, NCI funded, cooperative oncology trials group.